Best practices for managing ascites, volume overload & hyponatremia in cirrhosis.
Our new CPU in @AGA_Gastro shares 1️⃣3️⃣ evidence-based tips to support clinical decision-making.
Read more here: https://t.co/VT2rL72eIJ
@orman_md@BrettEFortuneMD@AsraniSumeet#GITwitter
@pgholam One the unique things in our field that we have treatments to offer for almost every condition we manage. From MASH to viral hepatitis to PBC,HCC, portal hypertension and decompensated cirrhosis. PSC and some rare exceptions. Super rewarding! Very few specialties can say that 😊
🚨 New insights on managing hepatitis delta virus (HDV):
Our new CPU, published in @AGA_Gastro, highlights screening, diagnosis, and therapies.
📖 Read more: https://t.co/zPQjjZDGPi
@TatyanaKushner@Robert_J_Wong#GItwitter
MASLD-HCC can occur in absence of cirrhosis
Our study 30,414 patients with MASLD in Hepatology
HCC risk ↑ by 18% per 5kPa ↑ in LSM
In pts with MASLD without cirrhosis, LSM of ≥10 kPa and diabetes, HCC risk is high enough to warrant screening
https://t.co/2oSOabOIxm
MASLD-HCC can occur in absence of cirrhosis
Our study 30,414 patients with MASLD in Hepatology
HCC risk ↑ by 18% per 5kPa ↑ in LSM
In pts with MASLD without cirrhosis, LSM of ≥10 kPa and diabetes, HCC risk is high enough to warrant screening
https://t.co/2oSOabOIxm
We need to spread the word about MASH
Awareness is low, particularly amongst people at risk and frontline providers
Hot of the presses in @HepCommJournal https://t.co/yowSsmKfNP #easl2025
Grateful for the invitation to speak @cddw_clm on "Remote evaluation of liver transplantation" in beautiful Quebec with some great speakers from @UofT . @CynthiaTsien@NaziaSelzner